World

Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note – Endpoints News

APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 

APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.

SOURCE: https://endpts.com/bluebird-lands-another-rare-disease-gene-therapy-ok-but-there-are-a-few-caveats-to-note/

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button